Cadrenal Therapeutics, Inc.
CVKD
$1.19
-$0.01-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 51.22% | -27.35% | |||
| Depreciation & Amortization | -16.67% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.85% | -17.97% | |||
| Operating Income | -32.85% | 17.97% | |||
| Income Before Tax | -33.09% | 17.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -33.09% | 17.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.09% | 17.85% | |||
| EBIT | -32.85% | 17.97% | |||
| EBITDA | -32.86% | 17.97% | |||
| EPS Basic | -9.99% | 27.57% | |||
| Normalized Basic EPS | -9.98% | 27.56% | |||
| EPS Diluted | -9.99% | 27.57% | |||
| Normalized Diluted EPS | -9.98% | 27.56% | |||
| Average Basic Shares Outstanding | 21.00% | 13.42% | |||
| Average Diluted Shares Outstanding | 21.00% | 13.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||